Administration of chondroprotector piascledine in the treatment of secondary osteoarthritis in patients with gout

Abstract

Objective. To study clinical efficacy and safety of piascledine in the treatment of osteoarthritis (OA) in pts with gout.Material and methods. 30 pts older than 35 years with gout and concomitant OA were included. During 2 months they received piascledine 300 mg/day. All pts fulfilled Wallace S. criteria for gout and ACR criteria for OA. Exclusion criteria: renal and hepatic failure,severe infections, childbearing potential female, administration of other chondroprotectors. Clinical and laboratory examination was performed before and after 2 months of treatment with piascledine.Results. After 2 months of treatment pain on VAS decreased at rest (p<0,01) and at movement (p<0,05). There were no adverse events leading to withdrawal of the drug. Uric acid serum level, measures of lipid and carbohydrate metabolism, renal and hepatic function did not significantly differ from baseline.Conclusion. Piascledine administration in gout pts with OA is safe, effectively decrease pain and do not influence serum level of uric acid.

Keywords

• gout
• osteoarthritis
• piascledine